In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its intention to go public. The autoimmune- and inflammatory-disease-focused ...

The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the 2021 highs. "I look for wherever I can make the most amount of money, legally, ...

Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings ...

While the major equity indexes have experienced a choppy Q4, a number of groups within the health care sector have shown strong resilience. Pharmaceuticals and biotechs have generally outperformed the ...

Like so many speculative growth ETFs and stocks, the S & P SPDR Biotech (XBI) ETF is nowhere close to its former all-time high from early 2021. It's currently 45% below its 2021 peak, and with the S & ...